- Previous Close
0.1570 - Open
0.1630 - Bid 0.1590 x --
- Ask 0.1630 x --
- Day's Range
0.1575 - 0.1650 - 52 Week Range
0.1400 - 0.3980 - Volume
803,483 - Avg. Volume
899,271 - Market Cap (intraday)
195.179M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which current therapy is lacking or in need of improvement. Its products under development that are in Phase II clinical trials include RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouchitis; and RNX-051 for the treatment of colorectal cancer and colon adenoma. The company was incorporated in 2002 and is based in Hørsholm, Denmark.
www.pharmaequitygroup.comRecent News: PEG.CO
View MorePerformance Overview: PEG.CO
Trailing total returns as of 1/31/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PEG.CO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PEG.CO
View MoreValuation Measures
Market Cap
195.18M
Enterprise Value
244.10M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
10.19
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-22.47%
Return on Equity (ttm)
-75.32%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-30.81M
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
863k
Total Debt/Equity (mrq)
169.42%
Levered Free Cash Flow (ttm)
-13.74M